SEHK:399

Stock Analysis Report

Innovative Pharmaceutical Biotech

Executive Summary

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Risks

  • Innovative Pharmaceutical Biotech is not covered by any analysts.

Share Price & News

How has Innovative Pharmaceutical Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

SEHK:399

-0.1%

HK Trade Distributors

-0.2%

HK Market


1 Year Return

-21.1%

SEHK:399

0.9%

HK Trade Distributors

-4.5%

HK Market

399 underperformed the Trade Distributors industry which returned 1.1% over the past year.

399 underperformed the Market in Hong Kong which returned -4.7% over the past year.


Share holder returns

399IndustryMarket
7 Day0%-0.1%-0.2%
30 Day-1.4%1.8%2.7%
90 Day-2.7%-7.8%-8.3%
1 Year-21.1%-21.1%5.7%0.9%-1.1%-4.5%
3 Year-30.4%-30.4%-14.8%-24.7%29.4%16.5%
5 Year-71.6%-71.6%-44.1%-53.0%21.3%1.0%

Price Volatility Vs. Market

How volatile is Innovative Pharmaceutical Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innovative Pharmaceutical Biotech undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Innovative Pharmaceutical Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Innovative Pharmaceutical Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 399’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Innovative Pharmaceutical Biotech regulatory filings.
  • Explore potentially undervalued companies in the capital goods industry.

Future Growth

How is Innovative Pharmaceutical Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

9.7%

Forecasted Trade Distributors industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovative Pharmaceutical Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Innovative Pharmaceutical Biotech performed over the past 5 years?

25.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Innovative Pharmaceutical Biotech does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Innovative Pharmaceutical Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Innovative Pharmaceutical Biotech's 1-year growth to the HK Trade Distributors industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used its assets last year compared to the HK Trade Distributors industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Innovative Pharmaceutical Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Innovative Pharmaceutical Biotech's financial position?


Financial Position Analysis

Innovative Pharmaceutical Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Innovative Pharmaceutical Biotech's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Innovative Pharmaceutical Biotech's level of debt (89.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (8.1% vs 89.8% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Innovative Pharmaceutical Biotech has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Innovative Pharmaceutical Biotech has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -69.8% per year.


Next Steps

Dividend

What is Innovative Pharmaceutical Biotech's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Innovative Pharmaceutical Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Innovative Pharmaceutical Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Innovative Pharmaceutical Biotech has not reported any payouts.

Unable to verify if Innovative Pharmaceutical Biotech's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Innovative Pharmaceutical Biotech has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Innovative Pharmaceutical Biotech's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Innovative Pharmaceutical Biotech has no CEO, or we have no data on them.


Management Age and Tenure

6.2yrs

Average Tenure

55yo

Average Age

The average tenure for the Innovative Pharmaceutical Biotech management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

8.1yrs

Average Tenure

62.5yo

Average Age

The tenure for the Innovative Pharmaceutical Biotech board of directors is about average.


Insider Trading

No 3 month individual insider trading information.


Ownership Breakdown


Management Team

  • Jie Gu (54yo)

    Adviser and Joint Chairman to the Department of Innovation & Strategic Development

    • Tenure: 3.6yrs
  • Yuan Xing Gao (64yo)

    Executive Director

    • Compensation: HK$928.00k
  • Dong Hui (57yo)

    General Manager of the Group and Director of CJV

  • Qi Dong (45yo)

    Sales Head of the Group

  • Hon Yin Poon (53yo)

    Financial Controller & Company Secretary

    • Tenure: 6.2yrs
  • Yumin Mao (67yo)

    Honorary Chairman & Chief Scientific Adviser

    • Tenure: 8.8yrs
  • Rong Tang (52yo)

    Executive Director

    • Compensation: HK$548.00k
  • Wei Ping Yu (61yo)

    Joint Chairman to the Department of Innovation & Strategic Development and Advisor

  • Yi Xie (56yo)

    Chief Executive of United Gane Holdings Limited

  • He Huang (38yo)

    Executive Director

    • Compensation: HK$668.00k

Board Members

  • Rongliang Wang (70yo)

    Independent Non-Executive Director

    • Tenure: 8.1yrs
    • Compensation: HK$60.00k
  • Yanmin Wu (42yo)

    Non-Executive Director

    • Tenure: 8.1yrs
    • Compensation: HK$60.00k
  • Zhihong Zhang (79yo)

    Independent Non-Executive Director

    • Tenure: 8.1yrs
    • Compensation: HK$60.00k
  • Yuan Xing Gao (64yo)

    Executive Director

    • Tenure: 3.5yrs
    • Compensation: HK$928.00k
  • Dong Hui (57yo)

    General Manager of the Group and Director of CJV

  • Nian Jiang (65yo)

    Chairman

    • Tenure: 8.1yrs
    • Compensation: HK$60.00k
  • Yumin Mao (67yo)

    Honorary Chairman & Chief Scientific Adviser

    • Tenure: 8.8yrs
  • Rong Tang (52yo)

    Executive Director

    • Tenure: 4.8yrs
    • Compensation: HK$548.00k
  • Weijun Chen (61yo)

    Independent Non-Executive Director

    • Tenure: 9.7yrs
    • Compensation: HK$80.00k
  • He Huang (38yo)

    Executive Director

    • Tenure: 2.5yrs
    • Compensation: HK$668.00k

Company Information

Innovative Pharmaceutical Biotech Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innovative Pharmaceutical Biotech Limited
  • Ticker: 399
  • Exchange: SEHK
  • Founded:
  • Industry: trading companies and distributors
  • Sector: capital goods
  • Market Cap: HK$519.789m
  • Shares outstanding: 1.46b
  • Website: Click here

Number of Employees


Location

  • Innovative Pharmaceutical Biotech Limited
  • West Tower Shun Tak Centre
  • Unit No. 2111
  • Sheung Wan
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
399SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDAug 2000
FRHNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

Biography

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong. The company also engages in the trading of beaut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/18 12:34
End of Day Share Price2019/06/21 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.